Enterprise Value

0.00

Cash

322.7M

Avg Qtr Burn

N/A

Short % of Float

27.80%

Insider Ownership

3.13%

Institutional Own.

81.30%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
OCALIVA® (obeticholic acid) Details
Primary biliary cholangitis, Infectious disease, COVID-19, Liver disease

Approved

Quarterly sales

Ocaliva + Bezafibrate Details
Primary biliary cholangitis, Liver disease

Phase 2

Update

INT-787 Details
Liver disease, Alcoholic hepatitis

Phase 2a

Update

Ocaliva Details
Primary sclerosing cholangitis, Liver disease

Failed

Discontinued

Ocaliva Details
Non-alcoholic steatohepatitis , Liver disease

Failed

Discontinued

Ocaliva Details
Non-alcoholic steatohepatitis , Liver disease

Failed

Discontinued